KBC Group NV decreased its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 18.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,910 shares of the specialty pharmaceutical company’s stock after selling 19,039 shares during the period. KBC Group NV owned approximately 0.23% of AMAG Pharmaceuticals worth $1,507,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMAG. State of Alaska Department of Revenue increased its position in AMAG Pharmaceuticals by 81.3% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 3,081 shares during the period. Advisors Asset Management Inc. increased its stake in shares of AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock valued at $156,000 after buying an additional 5,005 shares during the period. Mason Street Advisors LLC increased its stake in shares of AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $181,000 after buying an additional 554 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in shares of AMAG Pharmaceuticals by 6.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 510 shares during the period. Finally, Sei Investments Co. increased its stake in shares of AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after buying an additional 54 shares during the period.

AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at 16.55 on Thursday. The company’s market capitalization is $584.02 million. The firm’s 50-day moving average price is $18.67 and its 200 day moving average price is $20.39. AMAG Pharmaceuticals, Inc. has a one year low of $16.00 and a one year high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The firm had revenue of $158.39 million during the quarter, compared to analysts’ expectations of $158.83 million. During the same quarter last year, the company posted $1.45 earnings per share. The firm’s revenue was up 24.3% compared to the same quarter last year. On average, equities research analysts expect that AMAG Pharmaceuticals, Inc. will post ($1.38) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/08/31/kbc-group-nv-reduces-stake-in-amag-pharmaceuticals-inc-amag.html.

Several analysts have recently commented on AMAG shares. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Tuesday, July 11th. TheStreet downgraded AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Friday, May 5th. Barclays PLC reissued an “equal weight” rating and issued a $20.00 price objective (down from $25.00) on shares of AMAG Pharmaceuticals in a research note on Thursday, June 1st. Jefferies Group LLC reissued a “buy” rating and issued a $34.00 price objective (down from $40.00) on shares of AMAG Pharmaceuticals in a research note on Wednesday, May 3rd. Finally, ValuEngine downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $28.09.

In related news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the transaction, the senior vice president now owns 28,336 shares of the company’s stock, valued at $566,720. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 3.80% of the company’s stock.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.